Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05594017 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacological Modulation of Brain Oscillations in Memory Processing
A Early Phase 1 study of Epilepsy and Seizures, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05594017 is a Early Phase 1 study of Epilepsy and Seizures that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 60 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05594017, a Early Phase 1 study of Epilepsy and Seizures, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed. The main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is. Participants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and/or spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions. Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Scopolamine (0.4mg)
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2027-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05594017
The ClinicalTrials.gov registry entry for NCT05594017 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (94% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05594017 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05594017 about?
NCT05594017 is a clinical study titled "Pharmacological Modulation of Brain Oscillations in Memory Processing". The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure ...
What is the current status of trial NCT05594017?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2019-08-01. Estimated completion is 2027-05-31.
What conditions does trial NCT05594017 study?
This clinical trial studies the following conditions: Epilepsy, Seizures, Memory Loss, Memory Disorders, Cognitive Impairment, Mild.
What interventions are being tested in trial NCT05594017?
The interventions under investigation include: Placebo (DRUG), Scopolamine (0.4mg) (DRUG).
Who is sponsoring clinical trial NCT05594017?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05594017 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery
RECRUITING · Early Phase 1
-
Effect of Rose Odor Exposure on Ictal Apnea
RECRUITING · Early Phase 1
-
Localizing Epileptic Networks Using MRI and iEEG
RECRUITING · Early Phase 1
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.